Laboratory Of America Holdings Highlights Illume Fertility's Innovations at ASRM Congress
- Illume Fertility presents innovative research at the 2025 ASRM Congress, focusing on sperm processing and oocyte handling.
- Their studies validate existing sperm processing protocols and enhance embryo development methods, improving patient outcomes.
- Illume Fertility emphasizes collaboration and research to address evolving patient needs in reproductive medicine.
Illume Fertility Showcases Innovative Research at ASRM Congress
Illume Fertility, a leading fertility practice based in Norwalk, Connecticut, presents groundbreaking research at the 2025 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo held in San Antonio, Texas. The company highlights its commitment to advancing reproductive technology through two significant studies that illuminate new possibilities in sperm processing and oocyte handling. These studies represent Illume Fertility’s dedication to improving laboratory protocols and patient outcomes in the field of reproductive medicine.
The first study, directed by Maria J. Doukakis, MSc, with senior author Mark P. Leondires, MD, examines the impact of different centrifugal forces on density gradient processed semen samples. The results demonstrate that varying centrifugal forces do not significantly alter post-processing sperm concentration, motility, or total motile sperm counts. This finding reassures reproductive laboratories that current sperm processing protocols can remain unchanged, ultimately ensuring consistent quality in sperm handling. By validating existing methods, Illume Fertility reinforces its role as a trusted leader in reproductive health, allowing clinicians to focus on patient care without the concern of compromising sample integrity.
In a second pivotal study led by Erin E. DiPietro, PhD, and senior author Dara S. Berger, PhD, MPH, MS, researchers delve into the effectiveness of a low lactate, low glucose continuous culture medium during oocyte handling and conventional insemination. The findings reveal that this innovative medium achieves fertilization success rates comparable to traditional culture media while significantly enhancing usable blastocyst rates. This advancement is crucial for improving overall patient outcomes, as it provides a more efficient method for embryo development, thus aligning with Illume Fertility's mission to utilize evidence-based research in refining clinical practices.
Illume Fertility’s participation in the ASRM Congress not only showcases its commitment to scientific progress but also emphasizes its strategic focus on patient-centered care. By integrating innovative methodologies and optimized protocols, the company positions itself at the forefront of the fertility industry, significantly impacting family-building journeys for its patients. The studies presented serve as a testament to Illume Fertility’s efforts to shape the future of reproductive medicine, highlighting its ongoing dedication to harnessing research for the betterment of patient experiences.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

